SynthesisBMC infectious diseases2025
Antibiotic resistance and bacterial co-infections in COVID-19 patients in Iran: a systematic review and meta-analysis of hospitalized and non-hospitalized cases.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Hospital-Based Surveillance and Resistance Index Analysis of Antimicrobial Resistance Trends: A Three-Year Study from a Tertiary Hospital in Iran (2021-2023).Infection and drug resistance · 2026Article
- Antibiotic Prescribing in Patients Presenting with COVID-19: A Closed-Loop Audit with a Targeted Educational Intervention in a South Australian Hospital.Journal of clinical medicine · 2025Article
- Coinfections and superinfections in critically ill COVID-19 patients in Ecuador: a cross-sectional study of bacterial and viral pathogens.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe COVID-19 pandemic exacerbated antimicrobial resistance (AMR) in Iran, where up to 100% of hospitalized patients received antibiotics despite low bacterial co-infection rates. However, no comprehensive review has evaluated the burden of bacterial co-infections, antibiotic resistance (AR), and multi-drug resistance (MDR) across both hospitalized and non-hospitalized Iranian COVID-19 patients. This systematic review and meta-analysis aimed to determine the prevalence of bacterial infections, AR, and MDR during the COVID-19 era in Iran.
methodsFollowing PRISMA 2020 guidelines, we systematically searched MEDLINE (PubMed), Embase, Scopus, Web of Science, and Iranian regional databases for studies published from January 2020 to March 2025. The review protocol was registered with the Open Science Framework (OSF; https://doi.org/10.17605/OSF.IO/SCBRX ). Fifteen studies comprising 36,403 COVID-19 patients—33,989 inpatients (including 22,875 treated in intensive-care units) and 2,414 outpatients—met the inclusion criteria. We combined results from multiple studies to determine overall rates of bacterial infections, antibiotic resistance, and multi-drug resistance, using methods that account for differences between studies.
resultsThe pooled prevalence of bacterial co-infection among Iranian COVID-19 patients was 19.6% (95% CI: 17.8–21.4%) across hospitalized and non-hospitalized settings. Among hospitalized patients, secondary bacterial infections were predominantly caused by Gram-negative pathogens: Klebsiella pneumoniae (36.2%), Acinetobacter baumannii (28.4%), Escherichia coli (24.8%), and Pseudomonas aeruginosa (11.7%). High heterogeneity (I² >90%) was observed across most pooled estimates. Critical antimicrobial resistance rates were observed particularly in hospitalized settings, with carbapenem resistance reaching 91% for imipenem and 88% for meropenem in A. baumannii. Given that 63% of the cohort were ICU patients, the high secondary bacterial infection and resistance rates likely reflect risk factors such as mechanical ventilation and prolonged hospitalization.
conclusionIran’s AMR crisis during the COVID-19 era affects both hospitalized and non-hospitalized patients, with particularly concerning rates in healthcare settings. The predominance of hospitalized cases in available literature (ICU-heavy cohorts) reflects the urgent need for antimicrobial stewardship programs targeting hospital-based carbapenem-sparing regimens, while highlighting the need for improved surveillance across all COVID-19 care settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.